Coalition Against Major Diseases/European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer's disease

Alzheimer's and Dementia

Volumn 10, Issue 4, 2014, Pages 421-429.e3

  Hill, Derek L G ^a   Schwarz, Adam J ^b   Isaac, Maria ^c   Pani, Luca ^c   Vamvakas, Spiros ^c   Hemmings, Robert ^c   Carrillo, Maria C ^d   Yu, Peng ^b   Sun, Jia ^b,e   Beckett, Laurel ^f   Boccardi, Marina ^g   Brewer, James ^h   Brumfield, Martha ⁱ   Cantillon, Marc ^j   Cole, Patricia E ^b   Fox, Nick ^k   Frisoni, Giovanni B ^g   Jack, Clifford ^l   Kelleher, Thomas ^m   Luo, Feng ^m   Novak, Gerald ⁿ   Maguire, Paul ^o   Meibach, Richard ^p   Patterson, Patricia ^q   Bain, Lisa ^r   Sampaio, Cristina ^s   Raunig, David ^t   Soares, Holly ^m   Suhy, Joyce ^u   Wang, Huanli ^f   Wolz, Robin ^a,v   Stephenson, Diane ⁱ   more..

^a IXICO PLC   (United Kingdom)

^b ELI LILLY AND COMPANY   (United States)

^c EUROPEAN MEDICINES AGENCY   (United Kingdom)

^d ALZHEIMER'S ASSOCIATION   (United States)

^e UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ CRITICAL PATH INSTITUTE   (United States)

^j Wellnessmanagmentscom   (United States)

^k UNIVERSITY COLLEGE LONDON   (United Kingdom)

^l MAYO CLINIC   (United States)

^m BRISTOL MYERS SQUIBB   (United States)

ⁿ JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^o NOVARTIS PHARMA AG   (Switzerland)

^p Independent Science Writer ^*

^q ASTRAZENECA   (United Kingdom)

^r Independent Science Writer   (United States)

^s CHDI MANAGEMENT CHDI FOUNDATION   (United States)

^t ICON Medical Imaging   (United States)

^u SYNARC INC   (United States)

^v IMPERIAL COLLEGE LONDON   (United Kingdom)

more..

Author keywords

Alzheimer's disease; Alzheimer's Disease Neuroimaging Initiative; Hippocampal volume; Mild cognitive impairment

Indexed keywords

BIOLOGICAL MARKER;

ALZHEIMER DISEASE; ARTICLE; BRAIN SIZE; DEMENTIA; EUROPEAN MEDICINES AGENCY; HIPPOCAMPUS; HUMAN; MILD COGNITIVE IMPAIRMENT; NERVE DEGENERATION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; CLINICAL TRIAL (TOPIC); DISEASE COURSE; EUROPE; FACTUAL DATABASE; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; STATISTICS AND NUMERICAL DATA;

ALZHEIMER DISEASE; CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; DISEASE PROGRESSION; EUROPE; HIPPOCAMPUS; HUMANS; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; PROPORTIONAL HAZARDS MODELS; ROC CURVE;

EID: 84903598116     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2013.07.003     Document Type: Article

References (73)

1. C.R. Jack Jr., D.S. Knopman, W.J. Jagust, L.M. Shaw, P.S. Aisen, and M.W. Weiner et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade Lancet Neurol 9 2010 119 128
2. C.R. Jack Jr. Alliance for aging research AD biomarkers work group: structural MRI Neurobiol Aging 32 2011 S48 S57
3. B.M. Jedynak, A. Lang, B. Liu, E. Katz, Y. Zhang, and B.T. Wyman et al. A computational neurodegenerative disease progression score: method and results with the Alzheimer's Disease Neuroimaging Initiative cohort Neuroimage 63 2012 1478 1486
4. European Medicines Agency. Qualification of novel methodologies for drug development: guidance to applicants. Accessed November, 21, 2012. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/Regulatory-and- procedural-guideline/2009/10/WC500004201.pdf. 2012.
5. Food and Drug Administration. Innovation or stagnation: challenges and opportunity on the critical path to new medical products. Accessed February 26, 2013. Available from: http://www.fda.gov/ScienceResearch/SpecialTopics/ CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm077262.htm. 2004.
6. K. Romero, B. Corrigan, J. Neville, S. Kopko, and M. Cantillon Striving for an integrated drug development process for neurodegeneration: the Coalition Against Major Diseases Neurodegen Dis Manage 1 2011 1 7
7. European Medicines Agency. Qualification opinion of low hippocampal volume (atrophy) by MRI for use in regulatory clinical trials: in pre-dementia stage of Alzheimer's disease. Accessed November, 21, 2012. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/Regulatory-and-procedural- guideline/2011/10/WC500116264.pdf. 2011.
8. M.W. Weiner, D.P. Veitch, P.S. Aisen, L.A. Beckett, N.J. Cairns, and R.C. Green et al. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception Alzheimers Dement 8 2012 S1 S68
9. R.A. Sperling, C.R. Jack Jr., and P.S. Aisen Testing the right target and right drug at the right stage Sci Transl Med 3 2011 111 133
10. R.C. Petersen, G.E. Smith, S.C. Waring, R.J. Ivnik, E.G. Tangalos, and E. Kokmen Mild cognitive impairment: clinical characterization and outcome Arch Neurol 56 1999 303 308
11. R.C. Petersen, R.O. Roberts, D.S. Knopman, B.F. Boeve, Y.E. Geda, and R.J. Ivnik et al. Mild cognitive impairment: ten years later Arch Neurol 66 2009 1447 1455
12. P.N. Wang, H.C. Liu, J.F. Lirng, K.N. Lin, and Z.A. Wu Accelerated hippocampal atrophy rates in stable and progressive amnestic mild cognitive impairment Psychiatry Res 171 2009 221 231
13. M.S. Albert, S.T. Dekosky, D. Dickson, B. Dubois, H.H. Feldman, and N.C. Fox et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 270 279
14. B. Dubois, H.H. Feldman, C. Jacova, S.T. Dekosky, P. Barberger-Gateau, and J. Cummings et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria Lancet Neurol 6 2007 734 746
15. P.J. Visser, S. Vos, I. van Rossum, and P. Scheltens Comparison of International Working Group criteria and National Institute on Aging-Alzheimer's Association criteria for Alzheimer's disease Alzheimers Dement 8 2012 560 563
16. V. Jelic, M. Kivipelto, and B. Winblad Clinical trials in mild cognitive impairment: lessons for the future J Neurol Neurosurg Psychiatry 77 2006 429 438
17. R.C. Petersen Mild cognitive impairment clinical trials Nat Rev Drug Discov 2 2003 646 653
18. J.M. Schott, J.W. Bartlett, J. Barnes, K.K. Leung, S. Ourselin, and N.C. Fox Reduced sample sizes for atrophy outcomes in Alzheimer's disease trials: baseline adjustment Neurobiol Aging 31 2010 1452 1462
19. S.M. Nestor, E. Gibson, F.Q. Gao, A. Kiss, and S.E. Black A direct morphometric comparison of five labeling protocols for multi-atlas driven automatic segmentation of the hippocampus in Alzheimer's disease Neuroimage 66C 2012 50 70
20. J.L. Whitwell, C.R. Jack Jr., J.E. Parisi, D.S. Knopman, B.F. Boeve, and R.C. Petersen et al. Rates of cerebral atrophy differ in different degenerative pathologies Brain 130 2007 1148 1158
21. H. Braak, and E. Braak Neuropathological staging of Alzheimer-related changes Acta Neuropathol 82 1991 239 259
22. J.L. Whitwell, K.A. Josephs, M.E. Murray, K. Kantarci, S.A. Przybelski, and S.D. Weigand et al. MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study Neurology 71 2008 743 749
23. G.B. Frisoni, N.C. Fox, C.R. Jack Jr., P. Scheltens, and P.M. Thompson The clinical use of structural MRI in Alzheimer disease Nat Rev Neurol 6 2010 67 77
24. Schmand B, Huizenga HM, van Gool WA. Meta-analysis of CSF and MRI biomarkers for detecting preclinical Alzheimer's disease. Psychol Med 40:135-45.
25. P. Vemuri, H.J. Wiste, S.D. Weigand, L.M. Shaw, J.Q. Trojanowski, and M.W. Weiner et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change Neurology 73 2009 294 301
26. Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0, updated March 2011. Available from: http://www.cochrane-handbook.org edition.
27. Freesurfer. Available from: http://surfer.nmr.mgh.harvard.edu/.
28. A.M. Dale, B. Fischl, and M.I. Sereno Cortical surface-based analysis: I. Segmentation and surface reconstruction Neuroimage 9 1999 179 194
29. NeuroQuant. Available from: http://www.cortechs.net/products/neuroquant. php.
30. J.B. Brewer Fully-automated volumetric MRI with normative ranges: translation to clinical practice Behav Neurol 21 2009 21 28
31. R. Wolz, P. Aljabar, J.V. Hajnal, A. Hammers, and D. Rueckert LEAP: Learning Embeddings for Atlas Propagation Neuroimage 49 2010 1316 1325
32. J. Barnes, J. Foster, R.G. Boyes, T. Pepple, E.K. Moore, and J.M. Schott et al. A comparison of methods for the automated calculation of volumes and atrophy rates in the hippocampus Neuroimage 40 2008 1655 1671
33. K.K. Leung, J. Barnes, G.R. Ridgway, J.W. Bartlett, M.J. Clarkson, and K. Macdonald et al. Automated cross-sectional and longitudinal hippocampal volume measurement in mild cognitive impairment and Alzheimer's disease Neuroimage 51 2010 1345 1359
34. S. Auriacombe, C. Helmer, H. Amieva, C. Berr, B. Dubois, and J.F. Dartigues Validity of the free and cued selective reminding test in predicting dementia: the 3C study Neurology 74 2010 1760 1767
35. A. Convit, J. de Asis, M.J. de Leon, C.Y. Tarshish, S. De Santi, and H. Rusinek Atrophy of the medial occipitotemporal, inferior, and middle temporal gyri in non-demented elderly predict decline to Alzheimer's disease Neurobiol Aging 21 2000 19 26
36. R.S. Desikan, H.J. Cabral, B. Fischl, C.R. Guttmann, D. Blacker, and B.T. Hyman et al. Temporoparietal MR imaging measures of atrophy in subjects with mild cognitive impairment that predict subsequent diagnosis of Alzheimer disease AJNR Am J Neuroradiol 30 2009 532 538
37. R.S. Desikan, B. Fischl, H.J. Cabral, T.L. Kemper, C.R. Guttmann, and D. Blacker et al. MRI measures of temporoparietal regions show differential rates of atrophy during prodromal AD Neurology 71 2008 819 825
38. D.P. Devanand, G. Pradhaban, X. Liu, A. Khandji, S. De Santi, and S. Segal et al. Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease Neurology 68 2007 828 836
39. C. Eckerstrom, E. Olsson, M. Borga, S. Ekholm, S. Ribbelin, and S. Rolstad et al. Small baseline volume of left hippocampus is associated with subsequent conversion of MCI into dementia: the Goteborg MCI study J Neurol Sci 272 2008 48 59
40. A. Fellgiebel, P.R. Dellani, D. Greverus, A. Scheurich, P. Stoeter, and M.J. Muller Predicting conversion to dementia in mild cognitive impairment by volumetric and diffusivity measurements of the hippocampus Psychiatry Res 146 2006 283 287
41. A.S. Fleisher, S. Sun, C. Taylor, C.P. Ward, A.C. Gamst, and R.C. Petersen et al. Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment Neurology 70 2008 191 199
42. S. Galluzzi, C. Geroldi, R. Ghidoni, B. Paghera, G. Amicucci, and M. Bonetti et al. The new Alzheimer's criteria in a naturalistic series of patients with mild cognitive impairment J Neurol 257 2010 2004 2014
43. C.J. Galton, S. Erzinclioglu, B.J. Sahakian, N. Antoun, and J.R. Hodges A comparison of the Addenbrooke's Cognitive Examination (ACE), conventional neuropsychological assessment, and simple MRI-based medial temporal lobe evaluation in the early diagnosis of Alzheimer's disease Cogn Behav Neurol 18 2005 144 150
44. W.J. Henneman, J.D. Sluimer, J. Barnes, W.M. van der Flier, I.C. Sluimer, and N.C. Fox et al. Hippocampal atrophy rates in Alzheimer disease: added value over whole brain volume measures Neurology 72 2009 999 1007
45. S.K. Herukka, C. Pennanen, H. Soininen, and T. Pirttila CSF Abeta42, tau and phosphorylated tau correlate with medial temporal lobe atrophy J Alzheimers Dis 14 2008 51 57
46. C.R. Jack Jr., R.C. Petersen, M. Grundman, S. Jin, A. Gamst, and C.P. Ward et al. Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI Neurobiol Aging 29 2008 1285 1295
47. C.R. Jack Jr., R.C. Petersen, Y. Xu, P.C. O'Brien, G.E. Smith, and R.J. Ivnik et al. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD Neurology 55 2000 484 489
48. C.R. Jack Jr., R.C. Petersen, Y.C. Xu, P.C. O'Brien, G.E. Smith, and R.J. Ivnik et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment Neurology 52 1999 1397 1403
49. C.R. Jack Jr., M.M. Shiung, S.D. Weigand, P.C. O'Brien, J.L. Gunter, and B.F. Boeve et al. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI Neurology 65 2005 1227 1231
50. C.R. Jack Jr., H.J. Wiste, P. Vemuri, S.D. Weigand, M.L. Senjem, and G. Zeng et al. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease Brain 133 2010 3336 3348
51. K. Kantarci, R.C. Petersen, B.F. Boeve, D.S. Knopman, S.D. Weigand, and P.C. O'Brien et al. DWI predicts future progression to Alzheimer disease in amnestic mild cognitive impairment Neurology 64 2005 902 904
52. R.J. Killiany, B.T. Hyman, T. Gomez-Isla, M.B. Moss, R. Kikinis, and F. Jolesz et al. MRI measures of entorhinal cortex vs hippocampus in preclinical AD Neurology 58 2002 1188 1196
53. S.M. Landau, D. Harvey, C.M. Madison, E.M. Reiman, N.L. Foster, and P.S. Aisen et al. Comparing predictors of conversion and decline in mild cognitive impairment Neurology 75 2010 230 238
54. T.R. Stoub, E.J. Rogalski, S. Leurgans, D.A. Bennett, and L. deToledo-Morrell Rate of entorhinal and hippocampal atrophy in incipient and mild AD: relation to memory function Neurobiol Aging 31 2010 1089 1098
55. T. Tapiola, C. Pennanen, M. Tapiola, S. Tervo, M. Kivipelto, and T. Hanninen et al. MRI of hippocampus and entorhinal cortex in mild cognitive impairment: a follow-up study Neurobiol Aging 29 2008 31 38
56. P.J. Visser, P. Scheltens, F.R. Verhey, B. Schmand, L.J. Launer, and J. Jolles et al. Medial temporal lobe atrophy and memory dysfunction as predictors for dementia in subjects with mild cognitive impairment J Neurol 246 1999 477 485
57. P.J. Visser, F.R. Verhey, P.A. Hofman, P. Scheltens, and J. Jolles Medial temporal lobe atrophy predicts Alzheimer's disease in patients with minor cognitive impairment J Neurol Neurosurg Psychiatry 72 2002 491 497
58. J.L. Whitwell, M.M. Shiung, S.A. Przybelski, S.D. Weigand, D.S. Knopman, and B.F. Boeve et al. MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment Neurology 70 2008 512 520
59. A. Bakkour, J.C. Morris, and B.C. Dickerson The cortical signature of prodromal AD: regional thinning predicts mild AD dementia Neurology 72 2009 1048 1055
60. A.S. Fleisher, R. Raman, E.R. Siemers, L. Becerra, C.M. Clark, and R.A. Dean et al. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease Arch Neurol 65 2008 1031 1038
61. M. Lorenzi, M. Donohue, D. Paternico, C. Scarpazza, S. Ostrowitzki, and O. Blin et al. Enrichment through biomarkers in clinical trials of Alzheimer's drugs in patients with mild cognitive impairment Neurobiol Aging 31 2010 1443 1451
62. S. Debette, S. Seshadri, A. Beiser, R. Au, J.J. Himali, and C. Palumbo et al. Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline Neurology 77 2011 461 468
63. T. den Heijer, L.J. Launer, N.D. Prins, E.J. van Dijk, S.E. Vermeer, and A. Hofman et al. Association between blood pressure, white matter lesions, and atrophy of the medial temporal lobe Neurology 64 2005 263 267
64. E.S. Korf, L.R. White, P. Scheltens, and L.J. Launer Midlife blood pressure and the risk of hippocampal atrophy: the Honolulu Asia Aging Study Hypertension 44 2004 29 34
65. T.L. Strassburger, H.C. Lee, E.M. Daly, J. Szczepanik, J.S. Krasuski, and M.J. Mentis et al. Interactive effects of age and hypertension on volumes of brain structures Stroke 28 1997 1410 1417
66. K.B. Walhovd, A.M. Fjell, J. Brewer, L.K. McEvoy, C. Fennema-Notestine, and D.J. Hagler Jr. et al. Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease AJNR Am J Neuroradiol 31 2010 347 354
67. C.R. Jack Jr., M.A. Bernstein, N.C. Fox, P. Thompson, G. Alexander, and D. Harvey et al. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods J Magn Reson Imaging 27 2008 685 691
68. M. Boccardi, R. Ganzola, M. Bocchetta, M. Pievani, A. Redolfi, and G. Bartzokis et al. Survey of protocols for the manual segmentation of the hippocampus: preparatory steps toward a joint EADC-ADNI harmonized protocol J Alzheimers Dis 26 2011 61 75
69. J.J. Gomar, M.T. Bobes-Bascaran, C. Conejero-Goldberg, P. Davies, and T.E. Goldberg Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's Disease Neuroimaging Initiative Arch Gen Psychiatry 68 2011 961 969
70. N.H. Stricker, H.H. Dodge, N.M. Dowling, S.D. Han, E.A. Erosheva, and W.J. Jagust CSF biomarker associations with change in hippocampal volume and precuneus thickness: implications for the Alzheimer's pathological cascade Brain Imaging Behav 2012
71. S. Vos, I. van Rossum, L. Burns, D. Knol, P. Scheltens, and H. Soininen et al. Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI Neurobiol Aging 33 2012 2272 2281
72. P. Yu, R.A. Dean, S.D. Hall, Y. Qi, G. Sethuraman, and B.A. Willis et al. Enriching amnestic mild cognitive impairment populations for clinical trials: optimal combination of biomarkers to predict conversion to dementia J Alzheimers Dis 32 2012 373 385
73. European Medicines Agency. Qualification opinion of Alzheimer's disease novel methodologies/biomarkers for PET amyloid imaging (positive/negative) as a biomarker for enrichment, for use in regulatory clinical trials in predementia Alzheimer's disease. Accessed December 28, 2012. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/Regulatory-and-procedural- guideline/2012/04/WC500125018.pdf. 2012.